Angelini Pharma has finalized a definitive agreement to acquire Catalyst Pharmaceuticals for an equity value of approximately €3.5bn ($4.1bn). This move marks a strategic entry into the US market for the company, further consolidating its operational focus on brain health and the treatment of complex conditions. The transaction, which has received unanimous approval from the boards of both organizations, is projected to reach completion in the third quarter of 2026.
Through Catalyst Pharmaceuticals acquisition, Angelini Pharma will integrate the existing infrastructure and product portfolio of Catalyst Pharmaceuticals. The intent is to leverage these assets to advance a comprehensive rare disease therapeutic platform. Angelini Pharma plans to synthesize Catalyst’s resources with its own established expertise in brain health to enhance its global standing in the neurological sector.
The portfolio acquired includes several significant treatments for neuromuscular and neurological conditions:
- Firdapse (amifampridine), indicated for Lambert-Eaton myasthenic syndrome in patients aged six and older.
- Agamree (vamorolone), a corticosteroid treatment for Duchenne muscular dystrophy for patients two years and older.
- Fycompa (perampanel), an antiepileptic therapy for which rights were obtained by the acquired entity in 2023.
The Catalyst Pharmaceuticals acquisition will be executed via a cash transaction at $31.50 per share for all outstanding shares of Catalyst Pharmaceuticals. Financing for this rare disease acquisition is supported by BNP Paribas, acting as the sole global coordinator and underwriter, with additional participation from Blackstone funds and select international partners.
Following the finalization of the deal, Catalyst Pharmaceuticals will operate as a wholly owned subsidiary of Angelini Pharma. While the transaction significantly increases the footprint of Angelini Pharma in the US market, the company maintains Italy as its core strategic industrial base. The expansion is designed to build upon Angelini Pharma’s existing European operations, ensuring a unified strategy across both regions.
Completion of Catalyst Pharmaceuticals acquisition remains subject to customary closing conditions, including regulatory approval and the consent of shareholders of Catalyst Pharmaceuticals. By securing this US market position, the organization intends to strengthen its commitment to brain health innovation and long-term development in the field of rare neurological disorders.
